Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 42
Filtrar
1.
Osteoarthritis Cartilage ; 31(8): 1132-1143, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-37105396

RESUMEN

OBJECTIVE: To investigate host and gut-microbiota related Tryptophan metabolism in hand osteoarthritis (HOA). METHODS: The baseline serum concentration of 20 Tryptophan metabolites was measured in 416 HOA patients in a cross-sectional analysis of the DIGICOD cohort. Tryptophan metabolites levels, metabolite-ratios and metabolism pathway activation were compared between erosive (N = 141) and non-erosive HOA (N = 275) by multiple logistic regressions adjusted on age, BMI and sex. The association between Tryptophan metabolite levels and HOA symptoms was investigated by a Spearman's rank correlation analysis. RESULTS: Four serum Tryptophan metabolites, eight metabolite ratios and one metabolism pathway were associated with erosive HOA. Erosive HOA was negatively associated with Tryptophan (odds ratio (OR) = 0.41, 95% confidence interval [0.24-0.70]), indole-3-aldehyde (OR = 0.67 [0.51-0.90]) and 3-OH-anthranilic acid (OR = 1.32 [1.13-1.54]) and positively with 5-OH-Tryptophan levels (OR = 1.41 [1.13-1.77]). The pro-inflammatory kynurenine-indoleamine 2,3-dioxygenase pathway was upregulated in erosive HOA (OR = 1.60 [1.11-2.29]). Eleven metabolites were correlated with HOA symptoms and were mostly pain-related. Serotonin and N-acetyl serotonin levels were negatively correlated with number of tender joints. Indole-3-aldehyde level was negatively correlated and 3-OH-anthranilic acid, 3-OH-kynurenine and 5-OH-Tryptophan levels were positively correlated with number of patients-reported painful joints. Quinolinic acid and 3-OH-kynurenine levels correlated positively with AUSCAN pain. CONCLUSIONS: Tryptophan metabolites disturbance is associated with erosive HOA and pain and emphasize the role of low-grade inflammation and gut dysbiosis in HOA.


Asunto(s)
Osteoartritis , Triptófano , Humanos , Quinurenina , Estudios Transversales , Serotonina , Osteoartritis/diagnóstico , Dolor/complicaciones
2.
Osteoarthritis Cartilage ; 31(2): 138-139, 2023 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-36309133
4.
Osteoarthritis Cartilage ; 29(9): 1335-1345, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34144150

RESUMEN

OBJECTIVE: Cartilage loss observed in osteoarthritis (OA) is prevented when osteoclasts in the subchondral bone are inhibited in mice. Here, we investigated the role of the osteoclast secretome and of the lipid mediator sphingosine 1-phosphate (S1P) in chondrocyte metabolism and OA. MATERIALS AND METHODS: We used SphK1LysMCre and wild type mice to assess the effect of murine osteoclast secretome in chondrocyte metabolism. Gene and protein expressions of matrix metalloproteinase (Mmp) were quantified in chondrocytes and explants by RT-qPCR and Western blots. SphK1LysMCre mice or wild type mice treated with S1P2 receptor inhibitor JTE013 or anti-S1P neutralizing antibody sphingomab are analyzed by OA score and immunohistochemistry. RESULTS: The osteoclast secretome increased the expression of Mmp3 and Mmp13 in murine chondrocytes and cartilage explants and activated the JNK signaling pathway, which led to matrix degradation. JTE013 reversed the osteoclast-mediated chondrocyte catabolism and protected mice against OA, suggesting that osteoclastic S1P contributes to cartilage damage in OA via S1P/S1P2 signaling. The activity of sphingosine kinase 1 (SphK1) increased with osteoclast differentiation, and its expression was enhanced in subchondral bone of mice with OA. The expression of Mmp3 and Mmp13 in chondrocytes was low upon stimulation with the secretome of Sphk1-lacking osteoclasts. Cartilage damage was significantly reduced in SphK1LysMCre mice, but not the synovial inflammation. Finally, intra-articular administration of sphingomab inhibited the cartilage damage and synovial inflammation. CONCLUSIONS: Lack of S1P in myeloid cells and local S1P neutralization alleviates from osteoarthritis in mice. These data identify S1P as a therapeutic target in OA.


Asunto(s)
Condrocitos/metabolismo , Lisofosfolípidos/antagonistas & inhibidores , Osteoartritis/metabolismo , Osteoartritis/prevención & control , Osteoclastos/metabolismo , Secretoma/metabolismo , Esfingosina/análogos & derivados , Animales , Masculino , Ratones , Esfingosina/antagonistas & inhibidores
5.
Health Qual Life Outcomes ; 18(1): 173, 2020 Jun 08.
Artículo en Inglés | MEDLINE | ID: mdl-32513190

RESUMEN

BACKGROUND: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory musculoskeletal disease, manifesting as peripheral arthritis, enthesitis, dactylitis, spondylitis, and skin and nail psoriasis. A core set of domains for measuring the impact of PsA has been developed, including pain, patient global assessment, physical function, health-related quality of life (HRQoL), and fatigue. To understand the impact of PsA on health domains from a patient's perspective, a global survey was developed and results reported in the context of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaire. METHODS: An online patient-based global survey was conducted by The Harris Poll in Australia, Brazil, Canada, France, Spain, Taiwan, the UK, and the US between November 2, 2017 and March 12, 2018. Eligible patients were ≥ 18 years old with a diagnosis of PsA for > 1 year, had visited a rheumatologist/dermatologist in the past 12 months and reported using ≥ 1 synthetic/biologic disease-modifying antirheumatic drug for PsA. Patients reported on PsA severity and symptoms, and the impact of PsA on HRQoL. After survey completion, responses were aligned with PsAID health domains. Descriptive statistics and chi-square tests were conducted. RESULTS: This analysis included 1286 patients from eight countries. Most patients (97%) reported musculoskeletal symptoms relating to PsA in the past year. Common moderate/major impacts of PsA were on physical activity (78%), ability to perform certain activities (76%), work productivity (62%), and career path (57%). Skin/nail symptoms occurred in 80% of patients. Overall, 69% of patients reported that PsA had a moderate/major impact on emotional/mental wellbeing, 56% on romantic relationships/intimacy, and 44% on relationships with family and friends. Social impacts included emotional distress (58%), social shame or disapproval (32%), and ceased participation in social activities (45%). Over half of all patients experienced unusual fatigue over the past 12 months (52%). The health domains that patients reported as being impacted by PsA aligned with life impact domains of the patient-derived PsAID health domains. CONCLUSION: These results highlight the impact of PsA on multiple health domains from a patient perspective that should be considered during shared decision-making processes between healthcare providers and patients.


Asunto(s)
Artritis Psoriásica/fisiopatología , Calidad de Vida , Adulto , Artritis Psoriásica/psicología , Femenino , Salud Global , Humanos , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios
6.
Br J Dermatol ; 181(4): 866-869, 2019 10.
Artículo en Inglés | MEDLINE | ID: mdl-30980721

Asunto(s)
Acné Vulgar/diagnóstico , Artritis Infecciosa/diagnóstico , Artritis Psoriásica/diagnóstico , Enfermedades Autoinflamatorias Hereditarias/diagnóstico , Hidradenitis Supurativa/diagnóstico , Inmunosupresores/uso terapéutico , Fenotipo , Piodermia Gangrenosa/diagnóstico , Espondilitis Anquilosante/diagnóstico , Acné Vulgar/tratamiento farmacológico , Acné Vulgar/genética , Acné Vulgar/inmunología , Adolescente , Adulto , Edad de Inicio , Anticuerpos Antifúngicos/sangre , Anticuerpos Antifúngicos/inmunología , Artritis Infecciosa/tratamiento farmacológico , Artritis Infecciosa/genética , Artritis Infecciosa/inmunología , Artritis Psoriásica/tratamiento farmacológico , Artritis Psoriásica/genética , Artritis Psoriásica/inmunología , Análisis Mutacional de ADN , Femenino , Heterogeneidad Genética , Pruebas Genéticas , Enfermedades Autoinflamatorias Hereditarias/tratamiento farmacológico , Enfermedades Autoinflamatorias Hereditarias/genética , Enfermedades Autoinflamatorias Hereditarias/inmunología , Hidradenitis Supurativa/tratamiento farmacológico , Hidradenitis Supurativa/genética , Hidradenitis Supurativa/inmunología , Humanos , Masculino , Piodermia Gangrenosa/tratamiento farmacológico , Piodermia Gangrenosa/genética , Piodermia Gangrenosa/inmunología , Saccharomyces cerevisiae/inmunología , Espondilitis Anquilosante/tratamiento farmacológico , Espondilitis Anquilosante/genética , Espondilitis Anquilosante/inmunología , Síndrome , Resultado del Tratamiento , Adulto Joven
7.
Semin Arthritis Rheum ; 47(3): 451-455, 2017 12.
Artículo en Inglés | MEDLINE | ID: mdl-28779847

RESUMEN

INTRODUCTION: Tumoral calcinosis (TC) is a difficult-to-treat complication that can occur during several diseases such as dermatomyositis or genetic hyperphosphatemia. It is a painful and disabling condition that can lead to local complications including joint mobility reduction, cutaneous ulceration and superinfection. For the largest lesions, the treatment relies essentially on surgery. Intravenous sodium thiosulfate (STS) is efficient to treat calciphylaxis in patients undergoing hemodialysis. Local injections of STS seem efficient in superficial calcifications. OBJECTIVE: To report the efficacy and safety of intra-lesional injections of STS in tumoral calcinosis. RESULTS: We report two cases of successful intra-lesional injections of STS. A 44-year-old woman, with a history of dermatomyositis, presenting large subcutaneous calcifications in the right elbow, and a 42-year-old man, with a history of familial tumoral calcinosis, presenting large intramuscular calcifications in the right buttock, received weekly intra-lesional of 1-3g STS injections for 12 and 21 months, respectively. In both cases, the treatment relieved pain and greatly reduced the tumoral calcinosis with a very significant functional improvement without specific adverse effects. In case 1, TC size decreased from 28.7*56.0mm at baseline to 21.5*30.6mm at M12 treatment (59% reduction). In case 2, TC reduced from 167.5*204.3mm at baseline to 86.2*85.2mm at M21 treatment (79% reduction). CONCLUSION: Local injection of STS could be a promising therapeutic strategy for large and deep TC lesions and could therefore be an alternative to surgery.


Asunto(s)
Calcinosis/tratamiento farmacológico , Quelantes/administración & dosificación , Dermatomiositis/tratamiento farmacológico , Hiperfosfatemia/tratamiento farmacológico , Tiosulfatos/administración & dosificación , Adulto , Calcinosis/etiología , Dermatomiositis/complicaciones , Dermatomiositis/diagnóstico por imagen , Femenino , Factor-23 de Crecimiento de Fibroblastos , Humanos , Hiperfosfatemia/complicaciones , Hiperfosfatemia/genética , Inyecciones Intralesiones , Imagen por Resonancia Magnética , Masculino , Síndrome de Sjögren/complicaciones
8.
Ann Rheum Dis ; 76(1): 29-42, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27457514

RESUMEN

BACKGROUND: New drugs and new evidence concerning the use of established treatments have become available since the publication of the first European League Against Rheumatism (EULAR) recommendations for the management of gout, in 2006. This situation has prompted a systematic review and update of the 2006 recommendations. METHODS: The EULAR task force consisted of 15 rheumatologists, 1 radiologist, 2 general practitioners, 1 research fellow, 2 patients and 3 experts in epidemiology/methodology from 12 European countries. A systematic review of the literature concerning all aspects of gout treatments was performed. Subsequently, recommendations were formulated by use of a Delphi consensus approach. RESULTS: Three overarching principles and 11 key recommendations were generated. For the treatment of flare, colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), oral or intra-articular steroids or a combination are recommended. In patients with frequent flare and contraindications to colchicine, NSAIDs and corticosteroids, an interleukin-1 blocker should be considered. In addition to education and a non-pharmacological management approach, urate-lowering therapy (ULT) should be considered from the first presentation of the disease, and serum uric acid (SUA) levels should be maintained at<6 mg/dL (360 µmol/L) and <5 mg/dL (300 µmol/L) in those with severe gout. Allopurinol is recommended as first-line ULT and its dosage should be adjusted according to renal function. If the SUA target cannot be achieved with allopurinol, then febuxostat, a uricosuric or combining a xanthine oxidase inhibitor with a uricosuric should be considered. For patients with refractory gout, pegloticase is recommended. CONCLUSIONS: These recommendations aim to inform physicians and patients about the non-pharmacological and pharmacological treatments for gout and to provide the best strategies to achieve the predefined urate target to cure the disease.


Asunto(s)
Supresores de la Gota/uso terapéutico , Gota/tratamiento farmacológico , Corticoesteroides/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Técnica Delphi , Consejo Dirigido , Medicina Basada en la Evidencia , Gota/sangre , Gota/terapia , Humanos , Interleucina-1/antagonistas & inhibidores , Estilo de Vida , Educación del Paciente como Asunto , Brote de los Síntomas , Ácido Úrico/sangre
9.
Osteoarthritis Cartilage ; 24(12): 2069-2076, 2016 12.
Artículo en Inglés | MEDLINE | ID: mdl-27492465

RESUMEN

Given the dramatic increase in the number of total knee replacement (TKR) surgeries in developed countries, the issue of the best time for surgery needs to be addressed from an economic perspective. OBJECTIVE: To assess, from the perspective of the healthcare payer, the cost-utility of two surgical strategies in which knee replacement is performed at the early or late stage of the disease in patients with knee osteoarthritis (OA). DESIGN: Patient data and evidence from published literature on economic costs and outcomes in OA, including utilities, non-pharmacological, pharmacological and surgical options, combined with population life tables were entered in a Markov model of OA. The model represented the lifetime experience of a cohort of patients following their therapeutic management, discounting costs (euros) and utilities (quality-adjusted life-years) at 4% annually. RESULTS: In the base-case scenario, early TKR cost €6,624 more than late TKR (€76,223 vs €69,599) with a 0.15 gain in QALYs (18.675 vs 18.524). This yielded an incremental cost-utility ratio (ICUR) of 43,631 €/QALY. Sensitivity analyses of the most influential uncertain parameters were performed and did not modify the direction of the conclusions: early TKR cost between €3,655 and €7,194 more than late TKR with a gain in QALYs between 0.15 and 0.39. The ICUR ranged from 17,131 €/QALY to 48,241 €/QALY. CONCLUSION: Our data do not support the early TKR strategy over the late TKR strategy in knee OA patients from a medico-economic perspective.


Asunto(s)
Artroplastia de Reemplazo de Rodilla , Estudios de Cohortes , Análisis Costo-Beneficio , Humanos , Osteoartritis de la Rodilla , Años de Vida Ajustados por Calidad de Vida
10.
Osteoarthritis Cartilage ; 24(3): 494-502, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26403062

RESUMEN

OBJECTIVE: Hereditary hemochromatosis (HH) is a disease caused by mutations in the Hfe gene characterised by systemic iron overload and associated with an increased prevalence of osteoarthritis (OA) but the role of iron overload in the development of OA is still undefined. To further understand the molecular mechanisms involved we have used a murine model of HH and studied the progression of experimental OA under mechanical stress. DESIGN: OA was surgically induced in the knee joints of 10-week-old C57BL6 (wild-type) mice and Hfe-KO mice. OA progression was assessed using histology, micro CT, gene expression and immunohistochemistry at 8 weeks after surgery. RESULTS: Hfe-KO mice showed a systemic iron overload and an increased iron accumulation in the knee synovial membrane following surgery. The histological OA score was significantly higher in the Hfe-KO mice at 8 weeks after surgery. Micro CT study of the proximal tibia revealed increased subchondral bone volume and increased trabecular thickness. Gene expression and immunohistochemical analysis showed a significant increase in the expression of matrix metallopeptidase 3 (MMP-3) in the joints of Hfe-KO mice compared with control mice at 8 weeks after surgery. CONCLUSIONS: HH was associated with an accelerated development of OA in mice. Our findings suggest that synovial iron overload has a definite role in the progression of HH-related OA.


Asunto(s)
Hemocromatosis/complicaciones , Sobrecarga de Hierro/complicaciones , Osteoartritis/etiología , Animales , Cartílago Articular/patología , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Regulación de la Expresión Génica/fisiología , Hemocromatosis/genética , Hemocromatosis/metabolismo , Proteína de la Hemocromatosis , Hierro/metabolismo , Sobrecarga de Hierro/genética , Sobrecarga de Hierro/metabolismo , Metaloproteinasa 3 de la Matriz/metabolismo , Meniscos Tibiales/cirugía , Ratones Endogámicos C57BL , Ratones Noqueados , Mutación , Osteoartritis/metabolismo , Osteoartritis/patología , Estrés Mecánico , Membrana Sinovial/metabolismo
11.
Curr Med Res Opin ; 31 Suppl 2: 27-32, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26414734

RESUMEN

Recent epidemiological data suggest a progressive increase of serum levels of uric acid worldwide. This rise in the prevalence of hyperuricemia may be related to the epidemic diffusion of overweight and obesity as well as the shifts in diet with increased consumption of foods rich in purines, alcoholic consumption, and soft drinks sweetened with fructose. The rise in serum uric acid levels worldwide may be regarded as leading an increased risk for gout and other systemic diseases, especially in the cardio-renal system. Therefore, careful management of hyperuricemia with urate deposition is crucial to prevent or even treat those systemic diseases. Despite this, hyperuricemia and gout often remain untreated. This paper reviews current evidence on the management of hyperuricemia with urate deposition, with a focus on its most controversial aspects. This review is based on a PubMed/Embase database search for articles on hyperuricemia and its impact on cardiovascular and renal function.


Asunto(s)
Gota/terapia , Hiperuricemia/terapia , Ácido Úrico/sangre , Dieta/efectos adversos , Gota/epidemiología , Gota/etiología , Humanos , Hiperuricemia/etiología , Obesidad/complicaciones , Sobrepeso/complicaciones
12.
Osteoarthritis Cartilage ; 23(12): 2086-2093, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26187570

RESUMEN

OBJECTIVE: The European Society on Clinical and Economic aspects of Osteoporosis and Osteoarthritis (ESCEO) organised a working group to evaluate the need for updating the current European guideline on clinical investigation of drugs used in the treatment of osteoarthritis (OA). DESIGN: Areas of potential attention were identified and the need for modifications, update or clarification was examined. Proposals were then developed based on literature reviews and through a consensus process. RESULTS: It was agreed that the current guideline overall still reflects the current knowledge in OA, although two possible modifications were identified. The first relates to the number and timing of measurements required as primary endpoints during clinical trials of symptom-relieving drugs, either drugs with rapid onset of action or slow acting drugs. The suggested modifications are intended to take into consideration the time related clinical need and expected time response to these drugs - i.e., a more early effect for the first category in addition to the maintenance of effect, a more continuous benefit over the long-term for the latter - in the timing of assessments. Secondly, values above which a benefit over placebo should be considered clinically relevant were considered. Based on literature reviews, the most consensual values were determined for primary endpoints of both symptom-relieving drugs (i.e., pain intensity on a visual analogue scale (VAS)) and disease-modifying drugs (i.e., radiographic joint-space narrowing). CONCLUSIONS: This working document might be considered by the European regulatory authorities in a future update of the guideline for the registration of drugs in OA.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Glucocorticoides/uso terapéutico , Osteoartritis/tratamiento farmacológico , Guías de Práctica Clínica como Asunto , Viscosuplementos/uso terapéutico , Administración Oral , Corticoesteroides/uso terapéutico , Sulfatos de Condroitina/uso terapéutico , Inhibidores de la Ciclooxigenasa 2/uso terapéutico , Europa (Continente) , Glucosamina/uso terapéutico , Humanos , Ácido Hialurónico/uso terapéutico , Inyecciones Intraarticulares
13.
Eur Rev Med Pharmacol Sci ; 19(4): 630-9, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25753881

RESUMEN

OBJECTIVE: To increase the knowledge of epidemiology and treatment of gout in a 'real-life' setting, we conducted a large observational analysis (CACTUS) in two European countries, namely France and Greece. PATIENTS AND METHODS: This was a multicenter, cross-sectional, observational analysis, conducted in France and Greece. The analysis was conducted in a field-practice scenario, with both general practitioners and rheumatologists recruiting patients for inclusion. Treatment methods and drug prescriptions were left to the sole initiative of the participating physicians. A number of epidemiological and clinical characteristics were recorded in a single inclusion visit. Compliance to maintenance treatment was also monitored after the inclusion visit by monthly interview. RESULTS: In total 3079 patients were included. Hypertension was the most common co-morbidity (68%), followed by hypercholesterolemia (59%) and obesity (48%). Mean serum Uric Acid (sUA) concentration was 8.7 mg/dl. Almost all patients received life-style or dietary recommendations. At inclusion, 81.5% of patients were on a urate-lowering treatment. Most of these patients had been treated with allopurinol; this treat-ment had been interrupted for lack of reduction of sUA levels below 6 mg/dl (47%), lack of symptom relief (34%) or poor compliance (23%). At the inclusion visit, 98% of the patients were prescribed an urate-lowering treatment: 87% received febuxostat and 12% allopurinol alone. Satisfactory or very satisfactory compliance to febuxostat was recorded in 92% of the patients, versus 82% in patients on allopurinol. CONCLUSIONS: CACTUS provides an overview of characteristics of gouty patients and gout management. Education of patients by healthcare providers seem to be a pre-requisite to optimize the management of gout, a condition which remains poorly man-aged.


Asunto(s)
Gota/epidemiología , Gota/terapia , Adulto , Alopurinol/uso terapéutico , Estudios de Cohortes , Comorbilidad , Estudios Transversales , Europa (Continente)/epidemiología , Febuxostat , Femenino , Francia/epidemiología , Gota/sangre , Supresores de la Gota/uso terapéutico , Grecia/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Obesidad/tratamiento farmacológico , Cooperación del Paciente , Tiazoles/uso terapéutico , Ácido Úrico/sangre
14.
Osteoarthritis Cartilage ; 23(6): 851-9, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25655678

RESUMEN

PURPOSE: Recent studies have suggested that metabolic factors (obesity, diabetes, hypertension and dyslipidemia) and their clustering in metabolic syndrome (MetS) might be involved in the pathophysiology of knee osteoarthritis (OA). We investigated their impact on radiographic progression by an annualised measure of the joint space narrowing (JSN) of the medial tibiofemoral compartment. METHODS: 559 patients older than 50 years with symptomatic knee OA were recruited for the placebo arm of the SEKOIA trial. The presence of diabetes, hypertension and dyslipidemia was determined at baseline interview. Body mass index (BMI) was calculated, obesity was considered >30 kg/m(2). MetS was defined by the sum of metabolic factors ≥ 3. Minimal medial tibiofemoral joint space on plain radiographs was measured by an automated method at baseline and then annually for up to 3 years. RESULTS: The mean age of patients was 62.8 [62.2-63.4] years; 392 were women. A total of 43.8% was obese, 6.6% had type 2 diabetes, 45.1% hypertension, 27.6% dyslipidemia and 13.6% MetS. Mean annualised JSN was greater for patients with type 2 diabetes than without diabetes (0.26 [-0.35 to -0.17] vs 0.14 [-0.16 to -0.12] mm; P = 0.001). This association remained significant after adjustment for sex, age, BMI, hypertension and dyslipidemia (P = 0.018). In subgroup analysis, type 2 diabetes was a significant predictor of JSN in males but not females. The other metabolic factors and MetS were not associated with annualised JSN. CONCLUSION: Type 2 diabetes was a predictor of joint space reduction in men with established knee OA. No relationships were found between MetS or other metabolic factors and radiographic progression.


Asunto(s)
Diabetes Mellitus Tipo 2/complicaciones , Osteoartritis de la Rodilla/etiología , Anciano , Progresión de la Enfermedad , Método Doble Ciego , Femenino , Humanos , Masculino , Síndrome Metabólico/complicaciones , Persona de Mediana Edad , Obesidad/complicaciones , Osteoartritis de la Rodilla/diagnóstico por imagen , Osteoartritis de la Rodilla/patología , Dolor/etiología , Dimensión del Dolor/métodos , Radiografía , Factores de Riesgo , Índice de Severidad de la Enfermedad , Factores Sexuales
15.
Ann Rheum Dis ; 74(5): 836-42, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-24395556

RESUMEN

BACKGROUND: Gout therapy includes xanthine oxidase inhibitors (XOI) and colchicine, which have both been associated with decreased cardiovascular risk. However, their effects on major cardiac events, such as myocardial infarction (MI), need to be investigated further. OBJECTIVES: To investigate whether XOIs and colchicine are associated with decreased risk of MI. METHODS: This case-control study compared patients with first-ever MI and matched controls. Cases were recruited from the Pharmacoepidemiological General Research on MI registry. Controls were selected from a referent population (n=8444) from general practice settings. RESULTS: The study sample consisted of 2277 MI patients and 4849 matched controls. Use of allopurinol was reported by 3.1% of cases and 3.8 of controls, and 1.1% of cases and controls used colchicine. The adjusted OR (95% CI) for MI with allopurinol use was 0.80 (0.59 to 1.09). When using less stringent matching criteria that allowed for inclusion of 2593 cases and 5185 controls, the adjusted OR was 0.73 (0.54 to 0.99). Similar results were found on analysis by sex and hypertension status. Colchicine used was not associated with a decreased risk of MI (aOR=1.17 (0.70 to 1.93)). CONCLUSIONS: Allopurinol may be associated with a reduced risk of MI. No decreased risk of MI was found in colchicine users. Besides its urate-lowering property, allopurinol might have a cardioprotective effect.


Asunto(s)
Alopurinol/uso terapéutico , Colchicina/uso terapéutico , Supresores de la Gota/uso terapéutico , Gota/tratamiento farmacológico , Infarto del Miocardio/epidemiología , Anciano , Estudios de Casos y Controles , Femenino , Gota/epidemiología , Humanos , Hipertensión/epidemiología , Modelos Logísticos , Masculino , Persona de Mediana Edad , Factores Protectores
16.
Ann Rheum Dis ; 74(9): 1697-705, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24817417

RESUMEN

AIM: To test the efficiency of tumour necrosis factor blockers (adalimumab) in patients with painful refractory (non-responders to analgesics and non-steroidal anti-inflammatory drugs (NSAIDs)) hand osteoarthritis (OA). METHODS: We performed a randomised, double-blind, placebo-controlled, parallel group, multicentre study. Patients were randomised to: 1/1 adalimumab 40 mg for two subcutaneous injections at a 15-day interval or placebo and monitored for 6 months. The primary outcome was the percentage of patients with an improvement of more than 50% in global pain (Visual Analogue Scale) between week 0 (W0) and week 6 (W6). Secondary outcomes included the number of painful joints, swollen joints, morning stiffness duration, patient and practitioner global assessments, functional indexes for hand OA, and consumption of analgesics. Analysis on the mean primary outcome measure was done on patients who received at least one injection. RESULTS: 99 patients were recruited and 85 patients were randomised. Among them, 37 patients in the placebo group and 41 in the adalimumab group received at least one injection and were evaluated at W6 (n=78) on the main efficacy outcome. Mean age was 62 years, 85% were women, and mean level of pain was 62 mm at W0. At W6, 35.1% in the adalimumab group versus 27.3% in the placebo group had a pain reduction ≥50% (RR 1.12 (95% CI 0.82 to 1.54; p=0.48). There were no statistical differences for all secondary end points. The rate of adverse events was similar in the two groups. CONCLUSIONS: Adalimumab was not superior to placebo to alleviate pain in patients with hand OA not responding to analgesics and NSAIDs. TRIALS REGISTRATION NUMBER: NCT00597623.


Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Antirreumáticos/uso terapéutico , Articulaciones de la Mano , Osteoartritis/tratamiento farmacológico , Dolor/tratamiento farmacológico , Adalimumab , Anciano , Analgésicos/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Osteoartritis/complicaciones , Dolor/etiología , Dimensión del Dolor , Insuficiencia del Tratamiento , Resultado del Tratamiento
17.
Ann Rheum Dis ; 74(9): 1684-90, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24796335

RESUMEN

OBJECTIVES: In France, the prevalence of gout is currently unknown. We aimed to design a questionnaire to detect gout that would be suitable for use in a telephone survey by non-physicians and assessed its performance. METHODS: We designed a 62-item questionnaire covering comorbidities, clinical features and treatment of gout. In a case-control study, we enrolled patients with a history of arthritis who had undergone arthrocentesis for synovial fluid analysis and crystal detection. Cases were patients with crystal-proven gout and controls were patients who had arthritis and effusion with no monosodium urate crystals in synovial fluid. The questionnaire was administered by phone to cases and controls by non-physicians who were unaware of the patient diagnosis. Logistic regression analysis and classification and regression trees were used to select items discriminating cases and controls. RESULTS: We interviewed 246 patients (102 cases and 142 controls). Two logistic regression models (sensitivity 88.0% and 87.5%; specificity 93.0% and 89.8%, respectively) and one classification and regression tree model (sensitivity 81.4%, specificity 93.7%) revealed 11 informative items that allowed for classifying 90.0%, 88.8% and 88.5% of patients, respectively. CONCLUSIONS: We developed a questionnaire to detect gout containing 11 items that is fast and suitable for use in a telephone survey by non-physicians. The questionnaire demonstrated good properties for discriminating patients with and without gout. It will be administered in a large sample of the general population to estimate the prevalence of gout in France.


Asunto(s)
Artritis Reumatoide/diagnóstico , Gota/diagnóstico , Osteoartritis/diagnóstico , Espondiloartropatías/diagnóstico , Adulto , Anciano , Artritis/diagnóstico , Artritis/epidemiología , Artritis Reumatoide/epidemiología , Estudios de Casos y Controles , Estudios Epidemiológicos , Francia/epidemiología , Gota/epidemiología , Humanos , Modelos Logísticos , Persona de Mediana Edad , Osteoartritis/epidemiología , Sensibilidad y Especificidad , Espondiloartropatías/epidemiología , Encuestas y Cuestionarios , Teléfono
18.
Curr Med Res Opin ; 29 Suppl 3: 9-15, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23611367

RESUMEN

OBJECTIVES: This review presents the information available on the role of uric acid (UA) on metabolic risk and on the link between hyperuricemia and metabolic syndrome. METHODS: Key papers for inclusion were identified by a PubMed search and articles were selected according to their relevance for the topic, according to the authors' judgment. RESULTS AND CONCLUSIONS: An elevated UA is both strongly associated and predictive of the metabolic syndrome, and increasing evidence suggests that UA may have a causal role. The classical viewpoint that UA is simply an innocuous marker of metabolic syndrome that should not even be measured will likely have to be modified. Lowering UA may be a novel treatment target for preventing diabetes and justify prospective clinical trials on the possible benefits of the measurement and lowering of serum UA on multiple chronic disease end points.


Asunto(s)
Ácido Úrico/sangre , Animales , Medicina Basada en la Evidencia , Femenino , Humanos , Masculino , Modelos Animales , Factores de Riesgo
19.
J Orthop Res ; 31(6): 901-7, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23423846

RESUMEN

To measure the evolution of the serum levels of specific Osteoarthritis (OA) biomarker, Coll2-1 and Coll2-1 NO2 in knee osteoarthritic patients after viscosupplementation (VS). Fifty-one patients with unilateral symptomatic knee were recruited for this prospective open label study. They received three intra-articular injections of 2 ml of hyaluronic acid (Hylan GF-20) and were followed for 3 months. Walking pain was evaluated and serum samples were taken at each visit. Coll2-1 and Coll2-1 NO2 were measured in the serum using specific immunoassays. Variations over time of each parameter and predictive factor of response were studied. Forty-five patients were analyzed. The serum concentrations of Coll2-1 and Coll2-1 NO2 were significantly higher in KL III/IV patients compared to KL I/II patients at baseline and decreased systematically over time after VS. Its effect was ever more pronounced in patients with KL III/IV. The serum concentration of Coll2-1 was significantly lower at baseline in responders than in non-responders. This study suggests a rapid slowdown of type II collagen degradation and joint inflammation after VS with Hylan G-20 and gives additional information for the validation of accurate biomarkers for OA. The serum level of Coll2-1 appeared to be a predictive factor for response to treatment.


Asunto(s)
Colágeno Tipo II/sangre , Ácido Hialurónico/administración & dosificación , Osteoartritis de la Rodilla/tratamiento farmacológico , Fragmentos de Péptidos/sangre , Viscosuplementos/administración & dosificación , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Femenino , Humanos , Inyecciones Intraarticulares , Masculino , Persona de Mediana Edad , Osteoartritis de la Rodilla/sangre , Estudios Prospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...